THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen Inc. (NASDAQ: AMGN) will discuss the proposed Biologic License Application (BLA) for romiplostim, an investigational thrombopoietin mimetic peptibody, for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) today at the Oncologic Drugs Advisory Committee (ODAC). Patients with chronic ITP, a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia) face the risk of bleeding events. Treatment of thrombocytopenia in adult patients with chronic ITP is considered an unmet medical need by the U.S. Food and Drug Administration (FDA) and has received orphan drug designation.
